Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...
Courtly Observations is a recurring series by Erwin Chemerinsky that focuses on what the Supreme Court’s decisions will mean for the law, for lawyers and lower courts, and for people’s lives. Please ...
SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...
Amicus Financial Advisors, LLC (“Amicus”) was ranked by USA Today/Statista as the #33 Best Financial Advisory Firm in the nation, making Amicus the highest ranked firm in Texas. Founded in 2005 as a ...
(The Center Square) – The Washington State Attorney General’s Office is claiming that email communications regarding an amicus brief filed in support of Perkins Coie’s federal lawsuit concerned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback